Author Correction: Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin

Affiliations

• ¹ Department of Biomedical Engineering, Yale University, New Haven, CT, USA.
• ² Chemical and Environmental Engineering, School of Engineering and Applied Sciences, Yale University, New Haven, CT, USA.
• ³ Department of Chemistry, School of Engineering and Applied Sciences, Yale University, New Haven, CT, USA.
• ⁴ Toralgen Inc., Indianapolis, IN, USA.
• ⁵ Novartis Institutes for BioMedical Research, Basel, Switzerland.
• ⁶ Medicine and Molecular Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
• ⁷ Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
• ⁸ Department of Biomedical Engineering, Yale University, New Haven, CT, USA. tarek.fahmy@yale.edu.
• ⁹ Chemical and Environmental Engineering, School of Engineering and Applied Sciences, Yale University, New Haven, CT, USA. tarek.fahmy@yale.edu.
• ¹⁰ Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA. tarek.fahmy@yale.edu.